David Wurtman

David Wurtman, M.D., M.B.A. is an entrepreneurial leader focused on making biopharmaceutical assets and technologies more valuable. He has held industry leadership roles for over 20 years, most recently serving as President, CEO, and, Member of the Board of Directors of Lyric Pharmaceuticals, a clinical-stage pharmaceutical company he co-founded in 2013. Under his direction, Lyric advanced an intravenous small molecule drug for the treatment of enteral feeding intolerance in critically ill patients through four clinical studies in three years, including a major north American & European Phase 2 study, results from which have been published in the journal Intensive Care Medicine. He is the lead inventor on several patent filings related to clinical pharmacology; two of his applications are now issued. Prior to Lyric he was Vice President of Medical Affairs & Product Development at Kineta and had a successful career as an independent corporate & product development consultant to over twenty biopharmaceutical and platform technology clients including Plexxikon, Theravance, CNS Therapeutics, Adamas, Aerovance, Angiogenix, Urigen, Vaccinex, Invion and Coda Biotherapeutics. He has held senior positions at Protein Design Labs, Eos Biotechnology, Genzyme, and S.G. Cowen in corporate and commercial development. He has executed more than 25 licensing and partnering transactions and raised over $70MM from U.S. government and venture capital sources. David received his B.A. from Harvard College, M.D. from Harvard Medical School, and M.B.A. from the MIT Sloan School of Management. He completed a primary care internal medicine residency at Mt. Auburn Hospital, a Harvard teaching hospital, and practiced Primary Care medicine at Harvard Community Health Plan. He has been board-certified in Internal Medicine. He serves on the Board of GlycoMira Therapeutics.